Incorrect Email Address for Corresponding Author.

cohortatthe6-weeklandmarkanalysisofprogression-freesur-vival(PFS),with43ofthesepatientshavingaPD-L1TPSofless than 50% and 11 a PD-L1 TPS of 50% or greater. These num-bers are too small to allow detection of a statistically signifi-cant difference in PFS in either subgroup between individu-als with irAEs and those without irAEs. However, there was a nonsignificant finding of a longer PFS in patients with irAEs thaninthosewithoutsucheventsforthesubgroupswitheither a low (hazard ratio, 0.58; 95% CI, 0.29-1.16; log-rank P = .12) orhigh(hazardratio,0.19;95%CI,0.008-2.05;log-rank P = .16) PD-L1 TPS. Although further studies will be needed to con-firm these preliminary findings, they suggest that the occur-renceofirAEsmaybepredictiveofnivolumabefficacyatleast inpartinamannerindependentofthePD-L1expressionlevel on tumor cells.